3,4-dihydroxyphenylacetic acid has been researched along with Dyskinesia, Drug-Induced in 25 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa (l-DOPA, l-3,4-dihydroxyphenylalanine) is the most effective drug in the symptomatic treatment of Parkinson's disease (PD), but chronic use initiates a maladaptive process leading to l-DOPA-induced dyskinesia (LID)." | 1.46 | Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. ( Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H, 2017) |
| " Chronic administration of ceruletide (160 micrograms." | 1.29 | Effect of chronic ceruletide treatment on dopaminergic neurotransmitters, receptors and their mRNAs in the striatum of rats with dyskinesia induced by iminodipropionitrile. ( Asanuma, M; Hirata, H; Mori, A; Ogawa, N; Ota, Z, 1993) |
| "Pergolide mesylate is a potent dopamine agonist that is being evaluated clinically in Parkinson disease, hyperprolactinemia, and other diseases." | 1.26 | Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia. ( Clemens, JA; Fuller, RW; Hynes, MD, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (36.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morin, N | 1 |
| Morissette, M | 1 |
| Grégoire, L | 1 |
| Di Paolo, T | 2 |
| Andersen, AD | 1 |
| Blaabjerg, M | 1 |
| Binzer, M | 1 |
| Kamal, A | 1 |
| Thagesen, H | 1 |
| Kjaer, TW | 1 |
| Stenager, E | 1 |
| Gramsbergen, JBP | 1 |
| Dupre, KB | 2 |
| Eskow, KL | 2 |
| Steiniger, A | 1 |
| Klioueva, A | 1 |
| Negron, GE | 1 |
| Lormand, L | 1 |
| Park, JY | 2 |
| Bishop, C | 3 |
| Barnum, CJ | 1 |
| Dickinson, SO | 1 |
| Yabe, H | 1 |
| Choudhury, ME | 1 |
| Kubo, M | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Nomoto, M | 1 |
| Taylor, JL | 1 |
| Walker, PD | 1 |
| Buck, K | 1 |
| Ferger, B | 1 |
| Kolbe, H | 1 |
| Clow, A | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Jeste, DV | 2 |
| Doongaji, DR | 1 |
| Linnoila, M | 1 |
| Fuller, RW | 1 |
| Clemens, JA | 1 |
| Hynes, MD | 1 |
| See, RE | 1 |
| Hirata, H | 1 |
| Ogawa, N | 2 |
| Asanuma, M | 2 |
| Ota, Z | 1 |
| Mori, A | 1 |
| Iida, K | 1 |
| Iwata, E | 1 |
| Asanuma, SN | 1 |
| Gómez-Vargas, M | 1 |
| Miyazaki, I | 1 |
| Nakanishi, T | 1 |
| Lindner, MD | 1 |
| Cain, CK | 1 |
| Plone, MA | 1 |
| Frydel, BR | 1 |
| Blaney, TJ | 1 |
| Emerich, DF | 1 |
| Hoane, MR | 1 |
| Mohanakumar, KP | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Lohr, JB | 1 |
| Kuczenski, R | 1 |
| Bracha, HS | 1 |
| Moir, M | 1 |
| Johansson, PE | 1 |
| Terenius, L | 1 |
| Häggström, JE | 1 |
| Gunne, L | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| Drumheller, A | 1 |
| Frecska, E | 1 |
| Bagdy, G | 1 |
| Perenyi, A | 1 |
| Arato, M | 1 |
| Degrell, I | 1 |
| Mogyorosy, Z | 1 |
| Stahl, SM | 1 |
| Faull, KF | 1 |
| Barchas, JD | 1 |
| Berger, PA | 1 |
| Cross, AJ | 1 |
| Crow, TJ | 1 |
| Ferrier, IN | 1 |
| Johnson, JA | 1 |
| Johnstone, EC | 1 |
| Owen, F | 1 |
| Owens, DG | 1 |
| Poulter, M | 1 |
| Corsini, GU | 1 |
| Pintus, S | 1 |
| Chiueh, CC | 1 |
| Weiss, JF | 1 |
| Kopin, IJ | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Bédard, PJ | 1 |
| Boucher, R | 1 |
| Kozell, L | 1 |
| Sandyk, R | 1 |
| Wagner, GC | 1 |
| Fisher, H | 1 |
25 other studies available for 3,4-dihydroxyphenylacetic acid and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine; | 2017 |
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Di | 2008 |
The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Hydrox | 2009 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsan | 2009 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Ben | 2008 |
Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Erythrocyt | 1981 |
Elevated cerebrospinal fluid noradrenaline in tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Homovan | 1984 |
Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corticosterone; Dopamine; Dose-Response Relationship | 1982 |
Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-In | 1993 |
Effect of chronic ceruletide treatment on dopaminergic neurotransmitters, receptors and their mRNAs in the striatum of rats with dyskinesia induced by iminodipropionitrile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzazepines; Blotting, Northern; Ceruletide; Corpus Striat | 1993 |
Effects of repeated cyclosporin A administration on iminodipropionitrile-induced dyskinesia and TRE-/CRE-binding activities in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cell Nucleus; Corpus Striatum; Cyclic AMP; Cyclospor | 1998 |
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa | 1999 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; | 1990 |
Neuropeptide changes in a primate model (Cebus apella) for tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Cebus; Corpus Striatum; | 1990 |
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Aci | 1991 |
Multivariate analysis of monoamine indices in patients with chronic schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Brain; Dopamine; Dopamine beta-Hydroxylase; Dyskinesia, | 1989 |
CSF monamine metabolites in movement disorders and normal aging.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Female; Glycols; Ho | 1985 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1985 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
The effects of L-tryptophan on haloperidol-induced movement disorder in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Halope | 1987 |